NITROXIDES FOR USE IN TREATING OR PREVENTING CARDIOVASCULAR DISEASE
Pharmaceutical compositions are provided that are useful in treating cardiovascular disease. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of one or more genes related to the cardiovascular disease. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of cardiovascular disease. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl), and the cardiovascular disease is myocardial infarction.
1 - 3 . (canceled)
4 . A method, for altering intracellular levels of one or more proteins associated with cardiovascular disease resulting from myocardial infarction, comprising:
identifying an individual in need of altering levels of the cardiovascular disease-associated proteins; and
administering to that individual an effective amount of a nitroxide antioxidant selected from the group consisting of compounds having the following formulas:
wherein X is selected from O. and OH, and R is selected from COOH, CONH, CN, and CH 2 NH 2 ;
wherein X is selected from O. and OH, and R 1 is selected from CH 3 and spirocyclohexyl, and R 2 is selected from C 2 H 5 and spirocyclohexyl;
wherein X is selected from O. and OH and R is selected from CONH;
wherein X is selected from O. and OH and R is selected from H, OH, and NH 2 , the level of the cardiovascular disease-associated protein is increased, and the cardiovascular disease-associated protein is hepatocyte growth factor or adiponectin.
5 . A method for altering intracellular levels of one or more proteins associated with cardiovascular disease resulting from myocardial infarction, comprising:
identifying an individual in need of altering levels of the cardiovascular disease-associated proteins; and
administering to that individual an effective amount of a nitroxide antioxidant selected from the group consisting of compounds having the following formulas:
wherein X is selected from O. and OH, and R is selected from COOH, CONH, CN, and CH 2 NH 2 ;
wherein X is selected from O. and OH, and R 1 is selected from CH 3 and spirocyclohexyl, and R 2 is selected from C 2 H 5 and spirocyclohexyl;
wherein X is selected from O. and OH and R is selected from CONH;
wherein X is selected from O. and OH and R is selected from H, OH, and NH 2 , and wherein the level of the cardiovascular disease associated protein is decreased.
6 . The method of claim 5 , wherein the cardiovascular disease associated protein is caspase 3.
7 . A method for altering intracellular levels of one or more proteins associated with cardiovascular disease resulting from myocardial infarction, comprising:
identifying an individual in need of altering levels of the cardiovascular disease-associated proteins; and
administering to that individual an effective amount of a nitroxide antioxidant selected from the group consisting of compounds having the following formulas:
wherein X is selected from O. and OH, and R is selected from COOH, CONH, CN, and CH 2 NH 2 ;
wherein X is selected from O. and OH, and R 1 is selected from CH 3 and spirocyclohexyl, and R 2 is selected from C 2 H 5 and spirocyclohexyl;
wherein X is selected from O. and OH and R is selected from CONH;
wherein X is selected from O. and OH and R is selected from H, OH, and NH 2 , and wherein the cardiovascular disease is selected from the group consisting of ventricular remodeling and apoptosis of cardiac tissue.
8 - 16 . (canceled)
17 . A method for inhibiting the progresssion of cardiovascular disease that results from myocardial infarction and is associated with a protein, comprising:
identifying an individual affected by or at risk for the protein-associated cardiovascular disease; and
administering to that individual an amount of a nitroxide antioxidant effective to alter expression of a gene associated with the protein-associated cardiovascular disease, wherein the nitroxide antioxidant is selected from the group consisting of compounds having the following formulas:
wherein X is selected from O. and OH, and R is selected from COOH, CONH, CN, and CH 2 NH 2 ;
wherein X is selected from O. and OH, and R 1 is selected from CH 3 and spirocyclohexyl, and R 2 is selected from C 2 H 5 and spirocyclohexyl;
wherein X is selected from O. and OH and R is selected from CONH;
wherein X is selected from O. and OH and R is selected from H, OH, and NH 2 , and
where the expression of the gene is increased.
18 . The method of claim 17 , wherein the gene is hepatocyte growth factor or adiponectin.
19 . A method for inhibiting the progression of cardiovascular disease that results from myocardial infarction and is associated with a protein, comprising:
identifying an individual affected by or at risk for the protein-associated cardiovascular disease; and
administering to that individual an amount of a nitroxide antioxidant effective to alter expression of a gene associated with the protein-associated cardiovascular disease, wherein the nitroxide antioxidant is selected from the group consisting of compounds having the following formulas:
wherein X is select O. and OH, and R is selected from COOH, CONH, CN, and CH 2 NH 2 ;
wherein X is selected from O. and OH, and R 1 is selected from CH 3 and spirocyclohexyl, and R 2 is selected from C 2 H 5 and spirocyclohexyl;
wherein X is selected from O. and OH and R is selected from CONH;
wherein X is selected from O. and OH and R is selected from H, OH, and NH 2 , and
where the expression of the gene is decreased.
20 . The method of claim 19 , wherein the gene is caspase 3.
21 . A method for inhibiting the progression of cardiovascular disease that results from myocardial infarction and is associated with a protein, comprising:
identifying an individual affected by or at risk for the protein-associated cardiovascular disease; and
administering to that individual an amount of a nitroxide antioxidant effective to alter expression of a gene associated with the protein-associated cardiovascular disease, wherein the nitroxide antioxidant is selected from the group consisting of compounds having the following formulas:
wherein X is selected from O. and OH, and R is selected from COOH, CONH, CN, and CH 2 NH 2 ;
wherein X is selected from O. and OH, and R 1 is selected from CH 3 and spirocyclohexyl, and R 2 is selected from C 2 H 5 and spirocyclohexyl;
wherein X is selected from O. and OH and R is selected from CONH;
wherein X is selected from O. and OH and R is selected from H, OH, and NH 2 , and
wherein the protein-associated cardiovascular disease is ventricular remodeling.
22 . A method for inhibiting the progression of cardiovascular disease that results from myocardial infarction and is associated with a protein, comprising:
identifying an individual affected by or at risk for the protein-associated cardiovascular disease; and
administering to that individual an amount of a nitroxide antioxidant effective to alter expression of a gene associated with the protein-associated cardiovascular disease, wherein the nitroxide antioxidant is selected from the group consisting of compounds having the following formulas:
wherein X is selected from O. and OH, and R is selected from COOH, CONH, CN, and CH 2 NH 2 ;
wherein X is selected from O. and OH, and R 1 is selected from CH 3 and spirocyclohexyl, and R 2 is selected from C 2 H 5 and spirocyclohexyl;
wherein X is selected from O. and OH and R is selected from CONH;
wherein X is selected from O. and OH and R is selected from H, OH, and NH 2 , and
wherein the protein-associated cardiovascular disease is apoptosis of cardiac tissue.